Not a good buy right now: trend/momentum is still bearish (SMA_200 > SMA_20 > SMA_5 and MACD histogram negative and expanding), which is unfavorable for an impatient entry.
Price is sitting just below the pivot (40.325) and only modestly above near-term support (S1 39.164). That creates bounce potential, but it’s not a clean, high-conviction entry while momentum is deteriorating.
Options show mixed sentiment (bullish longer-term positioning but bearish near-term flow) with very elevated IV percentile, which reduces the edge of chasing shares today.
Trend: Bearish structure with moving averages stacked down (SMA_200 > SMA_20 > SMA_5), implying the intermediate trend remains weak.
Momentum: MACD histogram at -0.176 (below zero) and negatively expanding → downside momentum is strengthening, not bottoming yet.
RSI: RSI_6 at ~42.25 (neutral-to-weak). Not oversold enough to suggest a high-probability snapback by itself.
Levels to watch: Pivot 40.325 (needs reclaim for better long setup); Resistance R1 41.487 then R2 42.204. Support S1 39.164 then S2 38.447.
Short-horizon pattern stats (similar candlesticks): modest positive drift indicated (+0.58% next day; +2.56% next week; +7.35% next month), but current technicals argue against paying up immediately.
Options Data
Bullish
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio
Positioning vs flow: Open-interest PCR 0.59 suggests more calls outstanding (bullish longer-term positioning), but volume PCR 1.82 shows today’s trading leaned toward puts (more cautious/defensive near-term).
Volatility: 30D IV ~41.69 vs historical vol ~25.01 → options are pricing elevated uncertainty; IV percentile 93.6 indicates IV is near the high end of its recent range.
Activity: Today’s volume 2,545 vs 30-day avg (about 93% of avg) and open interest elevated (today vs OI avg ~115.5%), suggesting active hedging/speculation rather than complacency.
Takeaway: sentiment is mixed and expensive-vol conditions make “chase buys” less attractive right now.
Technical Summary
Sell
4
Buy
6
Positive Catalysts
can serve as a catalyst if results/guide surprise positively.
Neutral/Negative Catalysts
Technical backdrop is still bearish (downward MA stack + weakening MACD), increasing odds of a failed bounce.
Industry/operational headwinds: analysts cite “insurance headwinds,” elevated uninsured rates, and market share evolution as drags.
No supportive near-term news flow (no recent news) to provide an immediate catalyst.
Elevated IV (high percentile) implies the market expects bigger moves/uncertainty, often coinciding with choppier price action.
No notable supportive signals from hedge funds/insiders (both neutral). No recent congress trading data to confirm conviction buying.
Wall Street cons (bear case): insurance-related volume pressure and competitive/share dynamics; at least one major shop is outright underweight.
Wall Street analysts forecast CPRT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CPRT is 43.33 USD with a low forecast of 33 USD and a high forecast of 52 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast CPRT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CPRT is 43.33 USD with a low forecast of 33 USD and a high forecast of 52 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
2 Hold
1 Sell
Hold
Current: 39.880
Low
33
Averages
43.33
High
52
Current: 39.880
Low
33
Averages
43.33
High
52
Baird
Outperform
downgrade
$55 -> $52
AI Analysis
2025-11-21
Reason
Baird
Price Target
$55 -> $52
AI Analysis
2025-11-21
downgrade
Outperform
Reason
Baird lowered the firm's price target on Copart to $52 from $55 and keeps an Outperform rating on the shares. The firm updated its model as insurance headwinds persist.
Barclays
John Babcock
Underweight
maintain
$32 -> $33
2025-11-21
Reason
Barclays
John Babcock
Price Target
$32 -> $33
2025-11-21
maintain
Underweight
Reason
Barclays analyst John Babcock raised the firm's price target on Copart to $33 from $32 and keeps an Underweight rating on the shares following the fiscal Q1 report. The company's insurance volumes are showing the impact of elevated uninsured rates and "market share evolution," the analyst tells investors in a research note.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CPRT
